Key result
Evaluating revascularization versus medical therapy for ischemic cardiomyopathy requires accounting for fundamental treatment differences.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Unadjusted comparisons of revascularization and medical therapy in ischemic cardiomyopathy are invalid; leaves open questions on relative efficacy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chiew et al. (2025) studied this question. Modes of revascularization for ischemic cardiomyopathy evaluated in trials like REVIVED-BCIS2 and STICHES represent complex comparisons akin to comparing apples with oranges.
Synapse has enriched 10 related papers. Consider them for comparative context: